secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2026-08-06T11:01:22+00:00
Accession:  0001671927-26-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q2 2026: KIMMTRAK rev $115.9M (+18% YoY); net loss $0.8M; TEBE-AM enrollment nearing target
--------------------------------------------------------------------------------

- KIMMTRAK net revenue $115.9M in Q2 2026, up 18% YoY; US sales $74.9M, Europe $34.1M, international $6.9M.
- Net loss narrowed to $0.8M ($0.02 loss per share) from $10.3M loss in Q2 2025; H1 2026 net income $12.2M.
- Phase 3 TEBE-AM trial for 2L+ advanced cutaneous melanoma enrollment nearing 540 patients; topline data possible end of 2026.
- Five-year OS data: KIMMTRAK OS rate 16% vs 8% control; median OS 21.6 vs 16.9 months (HR 0.67).
- Brenetafusp monotherapy in heavily pretreated advanced melanoma: ORR 17%, DCR 67% at 160 mcg; supports Phase 3 PRISM-MEL-301 dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/0001671927-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/imcr-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001671927-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer